公开(公告)号：US11224653B2

公开(公告)日：2022-01-18

申请号：US16112016

申请日：2018-08-24

Applicant: Cephalon, Inc.

Inventor： Parameswaran Nair ,  Manali Mukherjee

IPC: A61K39/395 ,  A61K9/00 ,  A61P11/06 ,  C07K16/24 ,  C07K14/54 ,  A61K39/00

Abstract: Disclosed herein are methods of treating severe glucocorticoid-dependent eosinophilic asthma in a subject whose asthma has been inadequately controlled with subcutaneously-administered mepolizumab. Also provided are methods of predicting responsiveness to anti-IL-5 antibody treatment in a subject having severe glucocorticoid-dependent eosinophilic asthma.

公开(公告)号：US20190062421A1

公开(公告)日：2019-02-28

申请号：US16112016

申请日：2018-08-24

Applicant: Cephalon, Inc.

Inventor： Parameswaran Nair ,  Manali Mukherjee

IPC: C07K16/24 ,  A61P11/06

Abstract: Disclosed herein are methods of treating severe glucocorticoid-dependent eosinophilic asthma in a subject whose asthma has been inadequately controlled with subcutaneously-administered mepolizumab. Also provided are methods of predicting responsiveness to anti-IL-5 antibody treatment in a subject having severe glucocorticoid-dependent eosinophilic asthma.